NL8302416A - Vertraagd werkend geneesmiddel met daarin suloctidil. - Google Patents

Vertraagd werkend geneesmiddel met daarin suloctidil. Download PDF

Info

Publication number: NL8302416A
Authority: NL; Netherlands
Prior art keywords: release; slow; tablet; tablet according; suloctidil
Prior art date: 1982-07-06

Application number

NL8302416A

Other languages

English (en)

Dutch (nl)

Original Assignee

Lepetit Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-07-06

Filing date

1983-07-06

Publication date

1984-02-01

1983-07-06 Application filed by Lepetit Spa filed Critical Lepetit Spa

1984-02-01 Publication of NL8302416A publication Critical patent/NL8302416A/nl

Links

229960003967 suloctidil Drugs 0.000 title claims description 26
230000003111 delayed effect Effects 0.000 title description 3
BFCDFTHTSVTWOG-PXNSSMCTSA-N (1r,2s)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol Chemical compound CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-PXNSSMCTSA-N 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
BFCDFTHTSVTWOG-YLJYHZDGSA-N (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCN[C@H](C)[C@@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-YLJYHZDGSA-N 0.000 claims description 25
239000003814 drug Substances 0.000 claims description 14
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
239000013543 active substance Substances 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 10
235000000346 sugar Nutrition 0.000 claims description 9
239000001913 cellulose Substances 0.000 claims description 8
229920002678 cellulose Polymers 0.000 claims description 8
235000010980 cellulose Nutrition 0.000 claims description 8
229940124531 pharmaceutical excipient Drugs 0.000 claims description 7
239000004094 surface-active agent Substances 0.000 claims description 7
239000002202 Polyethylene glycol Substances 0.000 claims description 5
229920001223 polyethylene glycol Polymers 0.000 claims description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
229920000053 polysorbate 80 Polymers 0.000 claims description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
239000012024 dehydrating agents‎ Substances 0.000 claims description 4
-1 polyoxyethylene Polymers 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
239000003945 anionic surfactant Substances 0.000 claims description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 2
229930182830 galactose Natural products 0.000 claims description 2
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
239000008101 lactose Substances 0.000 claims description 2
239000000787 lecithin Substances 0.000 claims description 2
235000010445 lecithin Nutrition 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
239000002736 nonionic surfactant Substances 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
230000008961 swelling Effects 0.000 claims description 2
125000000129 anionic group Chemical group 0.000 claims 2
230000001147 anti-toxic effect Effects 0.000 claims 1
239000003440 toxic substance Substances 0.000 claims 1
239000003826 tablet Substances 0.000 description 51
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
239000008187 granular material Substances 0.000 description 21
239000000203 mixture Substances 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
239000000377 silicon dioxide Substances 0.000 description 11
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
239000012153 distilled water Substances 0.000 description 9
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 9
235000011389 fruit/vegetable juice Nutrition 0.000 description 8
230000000968 intestinal effect Effects 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000001506 calcium phosphate Substances 0.000 description 6
235000011010 calcium phosphates Nutrition 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
229920002472 Starch Polymers 0.000 description 5
229910000389 calcium phosphate Inorganic materials 0.000 description 5
238000009472 formulation Methods 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
238000000034 method Methods 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000008107 starch Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
229910002012 Aerosil® Inorganic materials 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
210000004051 gastric juice Anatomy 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
239000005995 Aluminium silicate Substances 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
235000012211 aluminium silicate Nutrition 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
235000019731 tricalcium phosphate Nutrition 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000181 anti-adherent effect Effects 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 2
239000007948 fast release tablet Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
235000020374 simple syrup Nutrition 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000002522 swelling effect Effects 0.000 description 2
OXLXSOPFNVKUMU-UHFFFAOYSA-N 1,4-dioctoxy-1,4-dioxobutane-2-sulfonic acid Chemical class CCCCCCCCOC(=O)CC(S(O)(=O)=O)C(=O)OCCCCCCCC OXLXSOPFNVKUMU-UHFFFAOYSA-N 0.000 description 1
BFCDFTHTSVTWOG-UHFFFAOYSA-N 2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCNC(C)C(O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000004174 erythrosine Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000007942 layered tablet Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000011282 treatment Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NL8302416A 1982-07-06 1983-07-06 Vertraagd werkend geneesmiddel met daarin suloctidil. NL8302416A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT22246/82A IT1198386B (it)	1982-07-06	1982-07-06	Un prodotto a rilascio protratto contenente il suloctidile
IT2224682		1982-07-06

Publications (1)

Publication Number	Publication Date
NL8302416A true NL8302416A (nl)	1984-02-01

Family

ID=11193604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8302416A NL8302416A (nl)	1982-07-06	1983-07-06	Vertraagd werkend geneesmiddel met daarin suloctidil.

Country Status (9)

Country	Link
JP (1)	JPS5927820A (fr)
BE (1)	BE897221A (fr)
CA (1)	CA1216523A (fr)
DE (1)	DE3324209A1 (fr)
FR (1)	FR2529784B1 (fr)
GB (1)	GB2123291B (fr)
IT (1)	IT1198386B (fr)
NL (1)	NL8302416A (fr)
PT (1)	PT76982B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0171457B1 (fr) *	1984-08-17	1992-03-25	The Wellcome Foundation Limited	Composition à libération contrôlée d'une substance active et sa fabrication
US5188840A (en) *	1985-09-26	1993-02-23	Chugai Seiyaku Kabushiki Kaisha	Slow-release pharmaceutical agent
DE3720757A1 (de) *	1987-06-24	1989-01-05	Bayer Ag	Dhp-manteltablette
CN1053570C (zh) *	1987-10-07	2000-06-21	默尔多药物公司	哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US5085865A (en) *	1989-04-12	1992-02-04	Warner-Lambert Company	Sustained release pharmaceutical preparations containing an analgesic and a decongestant
FI93924C (fi) *	1991-09-17	1995-06-26	Martti Lauri Antero Marvola	Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
JP2634757B2 (ja) *	1993-06-25	1997-07-30	鹿島建設株式会社	鉄筋コンクリート建築物の解体装置
IT1264696B1 (it) *	1993-07-09	1996-10-04	Applied Pharma Res	Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
GB9523752D0 (en) *	1995-11-21	1996-01-24	Pfizer Ltd	Pharmaceutical formulations
DE10031043A1 (de)	2000-06-26	2002-02-14	Bayer Ag	Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
EP1886671A1 (fr) *	2006-08-10	2008-02-13	The Jordanian Pharmaceutical Manufacturing Co.	Co-précipité d'amidon et silice, son procédé de préparation et son utilisation
EP1946750A1 (fr) *	2007-01-18	2008-07-23	The Jordanian Pharmaceutical Manufacturing Co.	Co-précipité, procédé de préparation de celui-ci et utilisations de celui-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3336200A (en) *	1963-05-28	1967-08-15	Warner Lambert Pharmaceutical	Tablet structure
GB1390748A (en) *	1973-04-09	1975-04-16	Continental Pharma	Alkyl and cycloalkylthiophenylalkylaminoalkanols their salts and the preparation thereof
FR2353288A1 (fr) *	1976-06-04	1977-12-30	Continental Pharma	Composition pharmaceutique hydrosoluble a base d'un compose amine comme produit actif

1982
- 1982-07-06 IT IT22246/82A patent/IT1198386B/it active
1983
- 1983-06-23 GB GB08317127A patent/GB2123291B/en not_active Expired
- 1983-07-05 JP JP58121135A patent/JPS5927820A/ja active Pending
- 1983-07-05 DE DE19833324209 patent/DE3324209A1/de not_active Withdrawn
- 1983-07-05 BE BE0/211122A patent/BE897221A/fr not_active IP Right Cessation
- 1983-07-05 PT PT76982A patent/PT76982B/pt unknown
- 1983-07-05 CA CA000431809A patent/CA1216523A/fr not_active Expired
- 1983-07-06 NL NL8302416A patent/NL8302416A/nl not_active Application Discontinuation
- 1983-07-06 FR FR8311275A patent/FR2529784B1/fr not_active Expired

Also Published As

Publication number	Publication date
FR2529784B1 (fr)	1986-03-28
IT8222246A0 (it)	1982-07-06
PT76982B (en)	1986-04-11
GB2123291B (en)	1986-06-25
GB8317127D0 (en)	1983-07-27
JPS5927820A (ja)	1984-02-14
FR2529784A1 (fr)	1984-01-13
GB2123291A (en)	1984-02-01
DE3324209A1 (de)	1984-01-12
BE897221A (fr)	1984-01-05
IT1198386B (it)	1988-12-21
CA1216523A (fr)	1987-01-13
PT76982A (en)	1983-08-01

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1988-03-01	BV	The patent application has lapsed

Publication	Publication Date	Title
EP0290168B1 (fr)	1991-09-25	Matrice d'ibuprofen à libération retardée et procédé
RU2453306C2 (ru)	2012-06-20	Твердые оральные дозируемые формы на основе вальсартана
KR100223131B1 (ko)	1999-10-15	서방성 약제 용량 단위
NL8500856A (nl)	1985-10-16	Bij opslag stabiele, snel uiteenvallende geperste voortbrengsels van een farmaceutisch werkzame stof alsmede een werkwijze ter vervaardiging ervan.
DK170110B1 (da)	1995-05-29	Farmaceutisk præparat med langsom frigivelse og anvendelse af fumarsyre til fremstilling af præpar atet
JPS62106011A (ja)	1987-05-16	徐放性錠剤
HK87893A (en)	1993-09-03	Orally sustained-release acetaminophen formulation and process to obtain it
KR20180082613A (ko)	2018-07-18	Urat1의 강력한 억제제를 포함하는 약학 조성물
CA1276560C (fr)	1990-11-20	Procede de production d'une preparation d'ibuprofen a liberation continue
CZ298851B6 (cs)	2008-02-27	Tableta pro rízené podávání úcinných látek
CA2416771C (fr)	2010-11-02	Acide 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetique pour le traitement de troubles relies au cox-2
RU2451504C2 (ru)	2012-05-27	Способ получения мультичастиц с применением роликового компактора
AU2002213900A1 (en)	2002-06-13	Pharmaceutical compositions
CA1216523A (fr)	1987-01-13	Comprime a delitement progressif contenant du suloctidil
IL192091A (en)	2012-04-30	Sustained release pharmaceutical compositions comprising liothyronine, process for their preparation and their use in the manufacture of medicaments
EP3854386B1 (fr)	2025-01-22	Composition pharmaceutique à désintégration orale comprenant du néfopam et son procédé de préparation
EP3024443A1 (fr)	2016-06-01	Composition pharmaceutique stable anti-tuberculose sous la forme d'un comprimé revêtu comprenant des granulés d'isoniazide et des granulés de rifapentine, et son procédé de préparation
US20090149543A1 (en)	2009-06-11	Solid pharmaceutical compositions comprising lumiracoxib
JP2000516601A (ja)	2000-12-12	水溶性化合物及びセルロースを含有する粒状物
EP0906754A1 (fr)	1999-04-07	Comprimes de s1452 a liberation rapide
CN120771158A (zh)	2025-10-14	预防血栓栓塞性疾病的药物组合物